Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

83.3%

5 terminated/withdrawn out of 6 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A
5(100.0%)
5Total
N/A(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT02446925Not ApplicableTerminated

Surefire Catheter Versus Standard End-hole Microcatheter: A Pilot Study

Role: collaborator

NCT03170869Not ApplicableTerminated

Bridge to Orthotopic Liver Transplantation (OLT) - Surefire Precision vs Endhole Embolization With DEBTACE

Role: collaborator

NCT03211598Not ApplicableUnknown

Surefire Institutional DEB-TACE

Role: collaborator

NCT03345225Not ApplicableWithdrawn

A Clinical Study of Precision TACE (P-TACE) With Surefire

Role: collaborator

NCT02967523Terminated

Surefire Precision Infusion System Registry

Role: lead

NCT02748161Not ApplicableTerminated

DEB-TACE for Hepatocellular Carcinoma

Role: lead

All 6 trials loaded